Farmakis M, Travlou O, Aroni S, Fertakis A
Intensive Care Unit of Metaxa Memorial Hospital, Piraeus, Greece.
Arzneimittelforschung. 1992 Aug;42(8):1041-4.
Nineteen randomized patients, treated with isoniazid (INH, CAS 54-85-3) for tuberculosis chemoprophylaxis or isoniazid plus rifampicin (RMP, CAS 13292-46-1) combination for tuberculosis therapy, were studied in order to explore the effects of these drugs on fibrinogen and antithrombin III blood levels. Other hepatic biology indices were also measured (aminotransferases, alkaline phosphatase, prothrombin time etc). The results suggested a relationship between INH or INH + RMP administration and fibrinogen as well as antithrombin III blood levels. The data indicate a protective effect of the RMP synchronous administration (by enzyme induction mechanisms) in the preservation of fibrinogen blood levels.
19名随机分组的患者参与了研究，这些患者接受异烟肼（INH，化学物质登记号54 - 85 - 3）进行结核病化学预防，或接受异烟肼加利福平（RMP，化学物质登记号13292 - 46 - 1）联合用药进行结核病治疗，目的是探究这些药物对纤维蛋白原和抗凝血酶III血液水平的影响。还测量了其他肝脏生物学指标（转氨酶、碱性磷酸酶、凝血酶原时间等）。结果表明，服用异烟肼或异烟肼 + 利福平与纤维蛋白原以及抗凝血酶III血液水平之间存在关联。数据表明，利福平同步给药（通过酶诱导机制）对维持纤维蛋白原血液水平具有保护作用。
